Tsubota Lab shares continued to decline as the company announced a joint research initiative with Falstoma to develop eye drops using ultra-fine bubble water.

The stock continued to decline. Following the close of trading on the 7th, the company announced that it had entered into a joint research agreement with Falstoma to develop eye drops using Ultra

Fisco JapanSep 8 13:02

With the market remaining sluggish, aggressive buying appears to be on hold.

[Emerging Markets Individual Stock Strategy]Today's emerging markets are expected to trade softly. Yesterday, the U.S. market was closed for Labor Day. In Europe, the UK's FTSE 100 fell 0.08%,

Fisco JapanSep 8 07:20

Steady performance; dip-buying may dominate [Individual Stock Strategy for Emerging Markets]

[Emerging Markets Individual Stock Strategy] The emerging markets are expected to show firm performance today. On the 19th, the U.S. stock market saw the Dow Inc average rise by $119.65 (+0.22%) to $53,463.05, marking its first rebound in four days. The announcement by the Treasury Department of an increase in long-term government bond buybacks was well received, leading to lower interest rates. However, the minutes from the July Federal Open Market Committee (FOMC) meeting indicated that participants highlighted the need for rate hikes if inflation did not slow down, causing the market to stall towards the end of the session. Today's emerging markets

Fisco JapanAug 20 07:20

Tsubota Lab: Significant revenue growth in Q1, with milestone-related revenue recognized.

Tsubota Labo <4890> announced its financial results for the first quarter of the fiscal year ending March 2027 (April–June 2026) on the 12th. Sales rose 766.7% year-on-year to JPY 215 million, while the operating loss narrowed to JPY 170 million (compared to a loss of JPY 217 million in the same period last year), the ordinary loss decreased to JPY 133 million (versus a loss of JPY 202 million previously), and the quarterly net loss stood at JPY 134 million (against a loss of JPY 202 million in the prior year). Regarding license agreements and the pharmaceutical development pipeline, the drug pipeline was publicly disclosed on October 15, 2024.

Fisco JapanAug 13 12:38

Tsubota Laboratory Narrows Quarterly Loss as Revenue Surges and Eyes Full-Year Profit

TipRanksAug 13 11:23

Tokio Marine reported a 11.5% year-on-year increase in ordinary profit for the first quarter, reaching 378.1 billion yen.

Tokio Marine Holdings (8766) reported consolidated results for the first quarter of the fiscal year ending March 2027, with ordinary profit rising 11.5% year-on-year to ¥378.167 billion and net income increasing 3..3% to ¥264.3 billion. Total consolidated assets increased by ¥674.3 billion from the end of the previous consolidated fiscal year to ¥33.6769 trillion. Ordinary profit exceeded the consensus estimate of ¥283.7 billion. [Positive Factors] Micronics Japan (6871) Mid-term | Hyuga Prima (7133) Quarterly | Narne (5870)

Fisco JapanAug 13 04:28